THỬ NGHIỆM, ĐÁNH GIÁ BỘ KIT AMPLISENS® HPV HCR GENOTYPE-FRT CHẨN ĐOÁN VÀ ĐỊNH TYPE HUMAN PAPILLOMA VIRUS
Nội dung chính của bài viết
Tóm tắt
EVALUATION OF A AMPLISENS® HPV HCR GENOTYPE-FRT FOR HUMAN PAPILLOMAVIRUS DETECTION AND GENOTYPING CAUSING CERVICAL CANCER
Persistent infection with oncogenic human papillomavirus (HPV) genotypes has been shown to be necessary for the development of cervical cancer. The recently developed AMPLISENS® HPV HCR GENOTYPE-FRT assay (HPV Amp-genotype assay) is based on simultaneous PCR (multiplex - PCR) and Real-time to detect 12 HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) and β-globin gene, used as internal control, in 4 tubes. Each HPV type is registered on its channel, that allows not only to detect the presence of HPV DNA, but also to differentitate the virus genotype. The aim of this study was to evaluate the performance of the HPV Amp-genotype assay for detecting HPV genotypes and comparing the results with those obtained in combination of the AmpliSens® HPV HCR screen-titre-FRT PCR 4x (HPV Amp-screen assay), LightPower HPV Genotype PCR-HPV GENOTYPE RDB (HPV GENOTYPE RDB assay) and Kit LightPower iVAHPV PCR Plus assay (PCR plus assay). We found high similarity between HPV Amp-genotype assay and others (88,09% - 86,6%- 89,55%; Cohen’s kappa coefficients = 0,745- 0,698-0,734). The limit of detection of HPV Amp-genotype assay was 1,14.103 copies/ml, it wasmore sensitive than other assays. In conclusion, the HPV Amp-genotype assay is an alternative test for HPV genotyping in clinical laboratories.
Từ khóa
Human papillomavirus (HPV), Genotyping, Real-time PCR Reverse Dot-blot hybridization, cervical cancer
Chi tiết bài viết
Tài liệu tham khảo
2. AmpliSens® HPV HCR genotype-FRT PCR kit Instruction Manual, Federal State Institution of Science Central Research Institute of Epidemiology
3. Bouvard V., Baan R., Straif K., Grosse Y., Secretan B., El Ghissassi F., A review of human carcinogens-Part B: biological agents, Lancet Oncol, 2009, 10, p.321-2.
4. Chung H.S., Lee M., Comparison of the AdvanSure HPV GenoBlot assay with the INNO-LiPA HPV Genotyping assay for human papillomavirus genotyping. Journal of Clinical Virology, 2014, 60, p.34-38.
5. Gravitt P.E., Coutlee F., Iftner T., Sellors J.W., Quint W.G., Wheeler C.M.,
New technologies in cervical cancer screening, Vaccine, 2008, 26(10):42-52.
6. HPV resources [online database]. World Health Organization http://www.who.int/nuvi/hpv/resources/en/index.htm/; 2013 [accessed 17.07.13].
7. Huang S.L., Chao A., Hsueh S., Chao F.Y., Huang C.C., Yang J., Lin C.Y.,
Yan C.C., Chou H.H., Huang K.G., Huang H.J., Wu T.L., Tseng M.J., Qiu J.T., Lin C.T., Chang T.C., Lai C.H., Comparision between the Hybrid Capture II Test and an SPF1/GP6+ PCR-Based Assay for Detection of Human Papillomavirus DNA in Cervical Swab Samples, Joural of Clinical Microbiology, 2006, 44(5):1733-1739.
8. Hwang Y., Lee M.D., Comparison of the AdvanSure Human Papillomavirus Screening Real-Time PCR, the Abbott RealTime High Risk Human Papillomavirus Test, and the Hybrid Capture Human Papillomavirus DNA Test for the Detection of Human Papillomavirus, Ann Lab Med, 2012, 32, p.201-205.
9. Krane J.F., Granter S.R., Trask C.E. et al., Papanicolaou smear sensitivity for the detection of adenocarcinoma of the cervix: a study of 49 cases, Cancer, 2001, 93, p.8-15.
10. Li N., Franceschi S., Howell-Jones R., Snijders P.J., Clifford G.M., Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication, Int J Cancer, 2011, 128, p.927-35.
11. Munoz N., Bosch F.X., De Sanjose S., Herrero R., Castllsague X., Shah K.V. et al., Epidemiologic classification of human papillomavirus types associates with-cervical cancer, N Engl J Med, 2003, 348, p.518-27.
12. Neerja B., MBBS, MD, FiCOG, FNAMS, Human papillomavirus deoxyribonucleic acid testing in developed countries, Besr Practice & Research Clinical Obstetrics and Gynaecology, 2012, 26, p.209-220.
13. Poljak M., Kocjan B.J., Commercially available assays for multiplex detection of alpha human papillomaviruses. Expert Rev Anti Infect Ther, 2010, 8, p.1139-62.
14. Sasieni P.D., Cuzick J. & Lynch-Farmery E., Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer, Br J Cancer, 1996, 73, p.1001-1005.
15. Schiffman M., Clifford G., Buonaguro F.M., Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline, Infect Agent Cancer, 2009, p.4:8.
16. Tucker R.A., Johnson P.R., Reeves W.C., Icenogle J.P., Using the polymerase chain reaction to genotype human papillomavirus DNAs samples containing multiple HPVs may produce inaccurate results, J Virol Methods, 1993, 43, p.321-333.
17. Zielinski G.D., Snijders P.J., Rozendaal L. et al., The presence of high-risk HPV combined with specific p53 and p16INK4a expression patterns points to high-risk HPV as the main causative agent for adenocarcinoma in situ and adenocarcinoma of the cervix, J Pathol, 2003, 201:535-543.